ライフサイエンスコーパス: cytogenetic abnormality

1 ide; each patient had trisomy 13 as the sole cytogenetic abnormality.

2 atients with lower-risk MDS with the del(5q) cytogenetic abnormality.

3 s-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality.

4 with an additional chromosome 19 as the sole cytogenetic abnormality.

5 a total of 53% of the patients had high-risk cytogenetic abnormalities.

6 osome 5q deletion with or without additional cytogenetic abnormalities.

7 opoiesis and an increase in the incidence of cytogenetic abnormalities.

8 al characteristics, pathologic features, and cytogenetic abnormalities.

9 ability to secondary recipients; and lack of cytogenetic abnormalities.

10 for severe X-linked diseases or X-chromosome cytogenetic abnormalities.

11 h long latency, low penetrance, and acquired cytogenetic abnormalities.

12 ave pronounced chromosome breakage and other cytogenetic abnormalities.

13 roves the poor PFS associated with high-risk cytogenetic abnormalities.

14 with Fanconi anemia universally bear complex cytogenetic abnormalities.

15 somy 8 was associated with other unfavorable cytogenetic abnormalities.

16 nto the effect of new drugs in patients with cytogenetic abnormalities.

17 me 13, deletion of Y chromosome, and complex cytogenetic abnormalities.

18 6.2%) were normal, and 434 (51.1%) had other cytogenetic abnormalities.

19 ns with increasingly shortened telomeres and cytogenetic abnormalities.

20 ridization (FISH) were used to detect clonal cytogenetic abnormalities.

21 Medulloblastomas exhibit an array of diverse cytogenetic abnormalities.

22 al or environmental exposure and presence of cytogenetic abnormalities.

23 ple myeloma (MM) outcome is driven mainly by cytogenetic abnormalities.

24 s defined by a combination of morphology and cytogenetic abnormalities.

25 s; in contrast, leiomyomas have simple or no cytogenetic abnormalities.

26 Five patients had previously undiagnosed cytogenetic abnormalities.

27 re similar for the patients with and without cytogenetic abnormalities.

28 groups, including in patients with high-risk cytogenetic abnormalities.

29 blasts or any specific type of leukemia cell cytogenetic abnormalities.

30 g-term continuous CR for patients with other cytogenetic abnormalities.

31 ding the prognostic implications of specific cytogenetic abnormalities.

32 al karyotype AML, and 88 patients with other cytogenetic abnormalities.

33 ion was found in five of 15 patients who had cytogenetic abnormalities.

34 ive therapy, but none were the patients with cytogenetic abnormalities.

35 hain variable region gene mutation status or cytogenetic abnormalities.

36 the high proportion of patients with adverse cytogenetic abnormalities.

37 types but lacking the classifcation defining cytogenetic abnormalities.

38 entity displayed significantly fewer adverse cytogenetic abnormalities.

39 lecular basis, characterized by nonrecurrent cytogenetic abnormalities.

40 sume this is true regardless of accompanying cytogenetic abnormalities.

41 ot able to overcome the adverse prognosis of cytogenetic abnormalities.

42 igh percentage of MDS HSC (92% +/- 4%) carry cytogenetic abnormalities.

43 al and clinical significance of the observed cytogenetic abnormalities.

44 dary molecular events, as well as additional cytogenetic abnormalities.

45 g a diploid karyotype or other miscellaneous cytogenetic abnormalities (14.2 pg/mL; P <.001).

46 d in the genetic etiology of AD based on (1) cytogenetic abnormalities; (2) increased recombination f

47 (.38 and.37) and patients with miscellaneous cytogenetic abnormalities (.52 and.49; P <.001 for each

48 re with the highest proportion of detectable cytogenetic abnormalities (76%; including 83% of all fav

49 other B-NHL cell lines examined with 12q24.1 cytogenetic abnormalities, a mediastinal B-NHL cell line

50 remission (CR); three of three patients with cytogenetic abnormalities achieved cytogenetic CR (none

51 Deletion 17p or 6q with or without other cytogenetic abnormalities, age at least 60 years, beta2-

52 Non-recurrent cytogenetic abnormalities also occur frequently cancerou

53 was no common immunophenotype or consistent cytogenetic abnormality, although all showed structural

54 cytogenetic results; 137 (25%) had high-risk cytogenetic abnormalities and 172 (32%) had 1q21 amplifi

55 in, and mice lacking both Suv39-h genes show cytogenetic abnormalities and an increased incidence of

56 determine whether miRNAs are associated with cytogenetic abnormalities and clinical features in acute

57 All cultures contain cytogenetic abnormalities and elevated flow-cytometric 4

58 tic syndromes (MDS) have high frequencies of cytogenetic abnormalities and evidence is accumulating o

59 Based on outcome for specific cytogenetic abnormalities and karyotype complexity, pati

60 F, we retrospectively examined the impact of cytogenetic abnormalities and karyotypic evolution on th

61 One such locus is on chromosome 7p, where cytogenetic abnormalities and loss of heterozygosity (LO

62 Human chromosome 3p cytogenetic abnormalities and loss of heterozygosity hav

63 ene expression data is used to identify both cytogenetic abnormalities and molecular pathways that ar

64 ed on multivariable Cox regression analyses, cytogenetic abnormalities and mutations in RUNX1, NRAS,

65 These cytogenetic abnormalities and mutations lead to increase

66 ng Fancc(-/-) cells have a high incidence of cytogenetic abnormalities and myeloid malignancies that

67 Superseding the adverse effects of cytogenetic abnormalities and other standard prognostic

68 C clone probably contributes to the frequent cytogenetic abnormalities and poor responses to chemothe

69 th multiple myeloma is dictated primarily by cytogenetic abnormalities and proliferative capacity of

70 major classes of constitutional, structural cytogenetic abnormalities and recent studies that explor

71 The relationship between specific cytogenetic abnormalities and response to treatment was

72 n analysis of 42 leukemia cases with various cytogenetic abnormalities and several normal controls, t

73 risk" group, defined as those with high-risk cytogenetic abnormalities and/or 1q21 amplification (HR,

74 Patients of all ages with very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tand

75 n patients with AML and trisomy 11 as a sole cytogenetic abnormality and in 11% of patients with AML

76 ression induces centrosome amplification and cytogenetic abnormalities, and (2) in Ph(+) CML, it syne

77 Dupriez score, cytogenetic abnormalities, and degree of marrow fibrosis

78 Of adults with de novo AML, 45% lack cytogenetic abnormalities, and identification of predict

79 impact in AML with CK, AML with MDS-related cytogenetic abnormalities, and in a revised definition (

80 Cytogenetic abnormalities appear to be increased in chil

81 Clonal cytogenetic abnormalities are a major risk factor for re

82 t duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor out

83 Certain cytogenetic abnormalities are associated with increased

84 Cytogenetic abnormalities are important clinical paramet

85 Although cytogenetic abnormalities are important prognostic facto

86 Cytogenetic abnormalities are increased in schizophrenia

87 Certain cytogenetic abnormalities are known to adversely impact

88 In acute myeloid leukemia (AML), cytogenetic abnormalities are present in more than half

89 In pediatric acute myeloid leukemia (AML), cytogenetic abnormalities are strong indicators of progn

90 ain-Fusion (LGF) model, which represents all cytogenetic abnormalities as combinations of loss, gain,

91 The roles of cytogenetic abnormalities as well as aberrant angiogenes

92 samples were evaluated for the occurrence of cytogenetic abnormalities as well as the expression leve

93 transplantation is critically determined by cytogenetic abnormalities, as previously defined by Inte

94 ble-region heavy chain gene mutation status, cytogenetic abnormalities assessed by fluorescent in sit

95 GHV) gene mutation status, CD49d status, and cytogenetic abnormalities assessed by interphase fluores

96 e 21 (AML1-ETO), is one of the most frequent cytogenetic abnormalities associated with acute myelogen

97 l anomalies represent one of the most common cytogenetic abnormalities associated with these diseases

98 Patients with AML and MDS who had cytogenetic abnormalities associated with unfavorable ri

99 lthough only one patient had the most common cytogenetic abnormality associated with secondary MDS/AL

100 l acute lymphoid leukemia without structural cytogenetic abnormalities at 11q23 and 9p22.

101 Cytogenetic abnormalities at chromosome 1q21 are among t

102 Patients with cytogenetic abnormalities at CR (n = 71) had significant

103 In multivariate analysis, persistent cytogenetic abnormalities at CR was an independent predi

104 = .001), but among patients with persistent cytogenetic abnormalities at CR, no significant differen

105 Among the patients with persistent cytogenetic abnormalities at CR, those who underwent SCT

106 ), as well as after adjustment for poor-risk cytogenetic abnormalities at diagnosis and platelet coun

107 Lymphadenopathy > or = 5 cm, but not cytogenetic abnormalities at HCT, predicted relapse.

108 dies have shown a loss of heterozygosity and cytogenetic abnormalities at the 3p region in ovarian, e

109 Risk for cytogenetic abnormalities based on features and size: sm

110 Four of seven evaluable responders with cytogenetic abnormalities before treatment had normal cy

111 Nineteen of 99 tumors with complex cytogenetic abnormalities, but none of 69 tumors with si

112 osis to investigate the prognostic impact of cytogenetic abnormalities by fluorescence in situ hybrid

113 Whether the presence of high-risk (HR) cytogenetic abnormalities by fluorescence in situ hybrid

114 intact Arf-p53 pathway, and did not display cytogenetic abnormalities by spectral karyotyping (SKY)

115 thalidomide arm in the one third exhibiting cytogenetic abnormalities (CA).

116 The presence of a metaphase cytogenetic abnormality (CA) is the key negative predict

117 myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete

118 Cytogenetic abnormalities (CAs) and more than seven FLs

119 Cytogenetic abnormalities (CAs) are known to be the prep

120 Metaphase cytogenetic abnormalities (CAs), especially of chromosom

121 Among the prognostic factors evaluated, cytogenetic abnormalities (CAs), which are present in on

122 nce for the one third of patients exhibiting cytogenetic abnormalities (CAs; P = .02), a well-recogni

123 Certain cytogenetic abnormalities common in AML may affect apopt

124 Detailed genomic studies have shown that cytogenetic abnormalities contribute to multiple myeloma

125 isease as well as in patients with high-risk cytogenetic abnormalities, defined as t(4;14), t(14;16),

126 All enrolled participants had high-risk cytogenetic abnormalities (deletion 17p, TP53 mutation,

127 three prognostic groups could be defined by cytogenetic abnormalities detected at presentation in co

128 s clinical trial confirms prospectively that cytogenetic abnormalities detected by FISH can predict o

129 Retrospective studies suggest cytogenetic abnormalities detected by interphase fluores

130 in chromosome 20q, or del(20q), are frequent cytogenetic abnormalities detected in hematologic malign

131 The presence of additional cytogenetic abnormalities did not modify the outcome of

132 Patients with multiple adverse cytogenetic abnormalities do not benefit from these agen

133 Several patients acquired additional clonal cytogenetic abnormalities during therapy, a finding with

134 For inv(16) AML, secondary cytogenetic abnormalities (especially +22) and male sex

135 nt, and treatment parameters showed that six cytogenetic abnormalities (ETV6-RUNX1, high hyperdiploid

136 Cytogenetic abnormalities; expression levels of the miR-

137 roup of acute myeloid leukemias with various cytogenetic abnormalities, failed to reveal MLF2 gene re

138 All eight patients who presented with cytogenetic abnormalities (five chromosome 5 or 7 abnorm

139 ous chromosomes are among the most prevalent cytogenetic abnormalities found in cancer cells.

140 of changes that recapitulates, in part, the cytogenetic abnormalities found in human APL.

141 condary mutations recapitulate, in part, the cytogenetic abnormalities found in human APL.

142 nosomy of chromosome 7 was the most frequent cytogenetic abnormality, found in 24% of patients.

143 rmalities, but none of 69 tumors with simple cytogenetic abnormalities, had mutations (P < .001).

144 A range of cytogenetic abnormalities has been detected in patterned

145 ukemia where the identification of nonrandom cytogenetic abnormalities has paved the way for the disc

146 Other clonal cytogenetic abnormalities have also been reported in the

147 Unique and shared cytogenetic abnormalities have been documented for margi

148 Cytogenetic abnormalities have been identified that allo

149 Bone marrow cytogenetic abnormalities have been observed among survi

150 Therefore recurring cytogenetic abnormalities have been used to segregate pa

151 r OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, P = .049).

152 In hematopathology, recurrent structural cytogenetic abnormalities herald diagnostic, prognostic

153 myeloma is typically associated with various cytogenetic abnormalities; however, these genetic change

154 of association of co-occurrence of high-risk cytogenetic abnormalities (HRCAs) with prognosis in pati

155 th NDMM with planed enrichment for high-risk cytogenetic abnormalities (HRCAs).

156 The acquisition of the cytogenetic abnormalities hyperdiploidy or translocation

157 Studies indicate that specific cytogenetic abnormalities, identified by classical G-ban

158 s variable have shown that higher numbers of cytogenetic abnormalities (ie, 5) have a worse overall s

159 he impact of the four most common interphase cytogenetic abnormalities in 28 CLL patients relative to

160 we aimed to reassess the prognostic value of cytogenetic abnormalities in a large series of 617 adult

161 TO translocation is one of the most frequent cytogenetic abnormalities in acute myeloid leukemia (AML

162 erarchial classification system for specific cytogenetic abnormalities in acute myeloid leukemia (AML

163 ncer of the blood, though specific recurring cytogenetic abnormalities in AML are strongly associated

164 t(16;16)(p13.1;q22), one of the most common cytogenetic abnormalities in AML, leads to expression of

165 ion with one of the most frequently observed cytogenetic abnormalities in AML, the t(8;21)(q22;q22) t

166 Moreover, the most common recurrent cytogenetic abnormalities in ASD involve maternally deri

167 We have improved our understanding of the cytogenetic abnormalities in CLL and soon may see identi

168 Further definition of common cytogenetic abnormalities in CLL make it appear that the

169 ome 7 and del(7q) [-7/del(7q)] are recurring cytogenetic abnormalities in hematologic malignancies, i

170 The cytogenetic abnormalities in lymphocytes are exuberant:

171 usion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelo

172 We developed a model to predict cytogenetic abnormalities in patients with multiple myel

173 The occurrence of cytogenetic abnormalities in patients years after presen

174 Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prosp

175 peractivation, centrosome amplification, and cytogenetic abnormalities in the bone marrow (BM).

176 correlate the gene expression profiles with cytogenetic abnormalities in these DLBCLs, we examined t

177 Cytogenetic abnormalities in these tumors are consistent

178 nt partner chromosomes represent a recurrent cytogenetic abnormality in B-cell non-Hodgkin's lymphoma

179 Trisomy 8 is a frequent cytogenetic abnormality in bone marrow cells in patients

180 usually associated with the appearance of a cytogenetic abnormality in bone marrow cells.

181 The 8;21 translocation is the most common cytogenetic abnormality in human acute myelogenous leuke

182 f chromosome 5q (del[5q]) is the most common cytogenetic abnormality in MDS.

183 The subsequent development of a clonal cytogenetic abnormality in nonrevertant cells suggests t

184 %) had trisomy 21 (or mosaicism) as the only cytogenetic abnormality in the blast cells.

185 ally monosomy 7 and trisomy 8, is a frequent cytogenetic abnormality in the myelodysplastic syndromes

186 Leiomyosarcomas typically have complex cytogenetic abnormalities; in contrast, leiomyomas have

187 The cytogenetic abnormalities included a deletion of all or

188 had a diploid karyotype and one had multiple cytogenetic abnormalities including monosomy 5 and 7.

189 2 years, relapse occurred in 2 patients, and cytogenetic abnormalities (including monosomy 7) were ob

190 Fifty percent had 3 cytogenetic abnormalities, including 30% with 5.

191 The other cytogenetic abnormalities, including complex and monosom

192 There are frequent cytogenetic abnormalities, including deletions of chromo

193 t across subgroups with individual high-risk cytogenetic abnormalities, including patients with del(1

194 of leukemias frequently defined by recurrent cytogenetic abnormalities, including rearrangements invo

195 is a B-cell malignancy stratified in part by cytogenetic abnormalities, including the high-risk copy

196 Various cytogenetic abnormalities, including those associated wi

197 d lymphoid cells that contained molecular or cytogenetic abnormalities indicating their malignant nat

198 Expression signatures for AML with cytogenetic abnormalities involving -5 or -7 were simila

199 the study of children with lissencephaly and cytogenetic abnormalities involving chromosome 17p, howe

200 A variety of cytogenetic abnormalities involving chromosome 7 have be

201 Two of six DPL lesions karyotyped had cytogenetic abnormalities involving chromosomes 7, 12, a

202 Identification of cytogenetic abnormalities is an important clue for the e

203 Although detection of any cytogenetic abnormality is considered to suggest higher-

204 Identification of the specific cytogenetic abnormality is one of the critical steps for

205 disease-specific (eg, presence of high-risk cytogenetic abnormalities) is important for prognosis an

206 Turner syndrome, one of the most common cytogenetic abnormalities, is characterised by complete

207 Complex karyotype, defined as 3 cytogenetic abnormalities, is prognostic of survival in

208 e that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this dis

209 e immune-modulatory agents to MDS-associated cytogenetic abnormalities (MDS-CA) and clinical MDS or a

210 MDS-associated cytogenetic abnormalities (MDS-CAs) were observed in 105

211 long-term survival for patients with FA with cytogenetic abnormalities, MDS, or acute leukemia is ach

212 Monosomy 3 of the primary tumor is the cytogenetic abnormality most strongly associated with th

213 outcomes in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome (MDS

214 e analyzed data on 113 patients with FA with cytogenetic abnormalities (n = 54), MDS (n = 45), or acu

215 inv(16)(p13q22) is one of the most frequent cytogenetic abnormalities observed in acute myeloid leuk

216 In 9 of 12 cases, the same cytogenetic abnormality observed at the time of MDS diag

217 tions of chromosome 7q to be the most common cytogenetic abnormality observed in SLVL, a leukemic var

218 The inv(16)(p13q22) and t(16;16)(p13;q22) cytogenetic abnormalities occur commonly in acute myeloi

219 Cytogenetic abnormalities of chromosome arm 9p occur fre

220 6.3, a region reported to be associated with cytogenetic abnormalities of obese patients.

221 isorders known to be caused by molecular and cytogenetic abnormalities of the proximal short arm of c

222 of segment 17q21-qter) is the most frequent cytogenetic abnormality of neuroblastoma cells.

223 ospectively studied the prognostic impact of cytogenetic abnormalities on a larger cohort of patients

224 (AML) to ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rat

225 onresponders and 2 responders, developed new cytogenetic abnormalities on eltrombopag, including 5 wi

226 nfounding effects of this preexisting marrow cytogenetic abnormality on the response to gene transfer

227 ched related donor transplantations who have cytogenetic abnormalities only have the best survival.

228 ], respectively; P < .001) and patients with cytogenetic abnormalities only versus MDS/acute leukemia

229 cases of AML and in cases with +11 as a sole cytogenetic abnormality, only one chromosome contains th

230 The rest of the patients had nonspecific cytogenetic abnormalities or lacked cytogenetic informat

231 multiple myeloma (MM) patients regardless of cytogenetic abnormalities or response to current treatme

232 es, regardless of risk status, as defined by cytogenetic abnormalities or the revised International S

233 ranulocyte count, the presence of additional cytogenetic abnormalities, or the presence of extramedul

234 Patients with cytogenetic abnormalities other than t(9;22), t(4;11), -

235 otype (CK), and myelodysplasia (MDS)-related cytogenetic abnormalities (P < .0001, each); and NPM1 mu

236 ALC less than 5 x 10(9)/L had lower rates of cytogenetic abnormalities (P = .0002) and higher rates o

237 have resulted in increased identification of cytogenetic abnormalities, particularly the presence of

238 for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts,

239 red cell aplasia, (2) the presence of clonal cytogenetic abnormality predicts poor response to immuno

240 and further characterization of some of the cytogenetic abnormalities present in this disease.

241 e loss of chromosome 7q (del(7q)), a somatic cytogenetic abnormality present in myelodysplastic syndr

242 ivariate analysis of pretreatment variables, cytogenetic abnormalities, present in 47% of patients wi

243 B hyperexpression are found in patients with cytogenetic abnormalities presenting a unfavorable progn

244 nfections is associated with myelodysplasia, cytogenetic abnormalities, pulmonary alveolar proteinosi

245 ognostic significance of many rare recurring cytogenetic abnormalities remains uncertain.

246 The cytogenetic abnormalities reported in this group of brea

247 ient exhibited an unclassified leukemia with cytogenetic abnormalities resulting in monosomy for 7p a

248 ion between 13q12 and 8p11 is the consistent cytogenetic abnormality seen in a nonspecific myeloproli

249 hen the prognostic impact of race, secondary cytogenetic abnormalities, sex, and response to salvage

250 increased beta2-microglobulin, patients with cytogenetic abnormalities such as chromosome 13 deletion

251 Select cytogenetic abnormalities such as del(17)(p13.1) and del

252 ltiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p),

253 Some recurrent cytogenetic abnormalities, such as t(8;16)(p11;p13), are

254 The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14)

255 dy with TRF less than 5.0 kb, 3 had acquired cytogenetic abnormalities, suggesting that telomere eros

256 searchers have focused on characterizing the cytogenetic abnormalities that are detectable by routine

257 ions of 7q are recurring leukemia-associated cytogenetic abnormalities that correlate with adverse ou

258 complex hyperdiploid karyotypes and diverse cytogenetic abnormalities that included recurring and no

259 has been shown that in some patients without cytogenetic abnormalities the otherwise repressed matern

260 cluding age, mutations in FLT3 and NPM1, and cytogenetic abnormalities, the HRs for LSC score in the

261 sses, we combined mutations in 47 genes with cytogenetic abnormalities to identify genetic associatio

262 way abnormalities can be linked to predicted cytogenetic abnormalities to identify likely candidate g

263 ar CI, 63% vs 34), >=2 concomitant high-risk cytogenetic abnormalities vs 0 (4-year CI, 59% vs 33%),

264 The incidence of secondary cytogenetic abnormalities was 32%.

265 ll transplantation, but no unique pattern of cytogenetic abnormalities was observed.

266 The prognostic significance of each specific cytogenetic abnormality was not assessable.

267 ned poor-risk group with few known recurring cytogenetic abnormalities, we performed gene expression

268 normal karyotype, 824 patients with AML with cytogenetic abnormalities were analyzed.

269 Complex cytogenetic abnormalities were associated with poorer su

270 nd risk factor measures of the subjects with cytogenetic abnormalities were compared with those of th

271 High-risk cytogenetic abnormalities were defined as del(17p), t(4;

272 Six cytogenetic abnormalities were identified as clinically

273 The most frequently observed cytogenetic abnormalities were loss of 3p (60%), gain of

274 The most common cytogenetic abnormalities were monosomy 7 or del(7q) (53

275 High-risk cytogenetic abnormalities were present in 22 (48%) patie

276 Complex cytogenetic abnormalities were present in all patients.

277 horter OS than whites when certain secondary cytogenetic abnormalities were present.

278 nal status was significant for both, whereas cytogenetic abnormalities were significant only for OS.

279 in situ hybridization for leukemia-specific cytogenetic abnormalities (when present) and by transpla

280 h to automatically screen for many recurrent cytogenetic abnormalities while adeptly classifying non-

281 g CNNs to accurately classify many recurrent cytogenetic abnormalities while being able to reliably d

282 ude that tumor endothelial cells can acquire cytogenetic abnormalities while in the tumor microenviro

283 osis (MBL) shares common immunophenotype and cytogenetic abnormalities with CLL, from which it is dis

284 their individual prognostic impact, specific cytogenetic abnormalities with more than or equal to 5 i

285 mia (AML) is driven by complex mutations and cytogenetic abnormalities with profound tumoral heteroge